J&J reports 77% response rate for subcutaneous amivantamab regimen in head and neck cancer
Question
J&J reports 77% response rate for subcutaneous amivantamab regimen in head and neck cancer
Direct answer
A 77% confirmed response rate supports J&J's Rybrevant label expansion into first-line solid tumor regimens, expanding commercial drug demand. — bullish pressure on MRK via combination therapy demand pull-through for pembrolizumab.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-26
- Published
- 2026-10-26
- Revision
- 1 · 2026-10-28
Cite as: Market Ontology, “J&J reports 77% response rate for subcutaneous amivantamab regimen in head and neck cancer”, revision 1, evidence through 2026-10-26. https://marketontology.com/catalysts/2026-10-26/j-j-reports-77-response-rate-for-subcutaneous-amivantamab-regimen-in-head-and-ne-afc0ea
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| MRK | ▲Bull | 1–4 weeks | combination therapy demand pull-through for pembrolizumab | 65 |
J&J reports 77% response rate for subcutaneous amivantamab regimen in head and neck cancer
A 77% confirmed response rate supports J&J's Rybrevant label expansion into first-line solid tumor regimens, expanding commercial drug demand. — bullish pressure on MRK via combination therapy demand pull-through for pembrolizumab.
Subcutaneous amivantamab was combined with pembrolizumab in the OrigAMI-4 study.
- SourceSubcutaneous amivantamab was combined with pembrolizumab in the OrigAMI-4 study.
- TransmissionA 77% confirmed response rate supports J&J's Rybrevant label expansion into first-line solid tumor regimens, expanding commercial drug demand.
- SummaryJ&J recorded a 77% overall response rate in the Phase 1b/2 OrigAMI-4 trial for subcutaneous Rybrevant. The trial paired amivantamab with pembrolizumab and carboplatin in head and neck squamous cell cancer. The data supports label extension beyond thoracic oncology into frontline recurrent solid tumors.
- MRKDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- MRK closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- MRK price vs. pre-event level
- MRK volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| MRK | Bullishagreed | 140.61 2026-10-26 | +0.86% | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-26J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous AmivantamabJNJ MRK+0.86%
- 2026-10-26J&J Reports 77% Response Rate in Phase 1b/2 Trial for Subcutaneous AmivantamabJNJ MRK+0.86%
- 2026-10-26Microbiotica presents Phase 1b melanoma data combining MB097 with KeytrudaMRK+0.86%
- 2026-10-26Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancerJNJ MRK+0.86%
- 2026-10-26Microbiotica presents Phase 1b melanoma data combining MB097 with KeytrudaMRK+0.86%
- 2026-10-26Microbiotica Reports Positive Phase 1b Trial for MB097 with PembrolizumabMRK+0.86%
- 2026-10-26Johnson & Johnson reports 77% response rate in Phase 1b/2 Rybrevant studyJNJ MRK+0.86%
- 2026-10-26Johnson & Johnson amivantamab combo reports 77% response rate in head and neck cancerJNJ MRK+0.86%
Find trades for this development
Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.
First 10 runs free
See today's live cards
Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.